Level Four Advisory Services LLC Sells 2,828 Shares of Biogen Inc. (NASDAQ:BIIB)

Level Four Advisory Services LLC trimmed its position in Biogen Inc. (NASDAQ:BIIB) by 27.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,469 shares of the biotechnology company’s stock after selling 2,828 shares during the quarter. Level Four Advisory Services LLC’s holdings in Biogen were worth $1,142,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Signaturefd LLC increased its stake in Biogen by 3.5% during the 4th quarter. Signaturefd LLC now owns 2,092 shares of the biotechnology company’s stock valued at $320,000 after purchasing an additional 71 shares in the last quarter. Quent Capital LLC grew its holdings in shares of Biogen by 31.9% during the fourth quarter. Quent Capital LLC now owns 298 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 72 shares during the last quarter. TD Private Client Wealth LLC increased its position in shares of Biogen by 25.0% during the third quarter. TD Private Client Wealth LLC now owns 385 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 77 shares in the last quarter. Principal Securities Inc. raised its holdings in shares of Biogen by 30.1% in the 4th quarter. Principal Securities Inc. now owns 337 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 78 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its position in Biogen by 1.6% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,018 shares of the biotechnology company’s stock valued at $767,000 after acquiring an additional 79 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $138.37 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. Biogen Inc. has a fifty-two week low of $128.51 and a fifty-two week high of $238.00. The stock has a market cap of $20.25 billion, a PE ratio of 12.37, a price-to-earnings-growth ratio of 1.51 and a beta of 0.01. The stock has a fifty day moving average of $141.88 and a 200-day moving average of $159.97.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. Equities research analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current year.

Insider Activity at Biogen

In other Biogen news, Director Stephen A. Sherwin sold 8,760 shares of the firm’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the transaction, the director now directly owns 11,318 shares of the company’s stock, valued at $1,697,926.36. This trade represents a 43.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have commented on the company. The Goldman Sachs Group decreased their price objective on Biogen from $281.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 13th. William Blair reiterated an “outperform” rating on shares of Biogen in a report on Monday, January 13th. Jefferies Financial Group cut Biogen from a “buy” rating to a “hold” rating and dropped their price objective for the company from $250.00 to $180.00 in a research note on Monday, December 9th. Royal Bank of Canada reduced their target price on shares of Biogen from $231.00 to $225.00 and set an “outperform” rating for the company in a research note on Thursday, February 13th. Finally, HC Wainwright dropped their price target on shares of Biogen from $300.00 to $241.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Seventeen investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $213.33.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.